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Targeting Epilepsy Genes Minireview
Jeffrey L. Noebels steps taken by gene errors to destabilize neural net-
Developmental Neurogenetics Laboratory works; the first practical issue is which gene to select.
Department of Neurology In vitro studies have defined a pyramid of molecular
Section of Neurophysiology candidates for reversible epileptiform bursting in neu-
Baylor College of Medicine rons, beginning with ion channels and the receptors
Houston, Texas 77030 that gate them. Abnormal modulation of these primary
currents by derangements in the extra- and intracellular
ionic and second messenger environment provides the
Had epilepsy never existed, it would have been redis- next layer of potential gene modifiers; the broad base
covered eight times over in the past year by those intent of genes for developmental network assembly and plas-
on knocking out mouse genes one at a time. Adding ticity expands the list of plausible targets for epilepsy
extra copies of genes worked too. Feared since ancient candidate loci tomany hundreds of alleles. While it could
times for their unpredictable appearance in humans, be argued that deleting all of the prime candidates for
seizures have suddenly found an unusual welcome as inhibition, (e.g., genes for repolarizing K1 channels and
visible markers of cerebral dysfunction in transgenic GABA receptors) and screening for epilepticphenotypes
mice. The high incidence of the phenotype was less would be superfluous, the developmental attributes of
surprising than the broad range of functional defects these null subunit syndromes cannot be predicted, and
represented, since the gene errors for most human epi- in some (see below) epilepsy does not occur. Con-
lepsies are unknown and it is unclear whether they arise versely, structural point mutations in depolarizing ion
from a few common mutations or many rare ones. What channels might be anticipated to lead only to irreversible
can be learned from each of these newly created epi- bursting rather than to a stable epileptic phenotype.
lepsy models in mice? Do they pinpoint new excitability However, paroxysmal phenotypes have arisen sponta-
mechanisms and novel targets for human therapy, or neously in muscle channelopathies and could easily do
do they lead the way to cures for diseases that don't so in brain. At this early stage of analysis, none of the
exist? large number of mapped spontaneous epilepsy mutants
First, a definition, since theepilepsies comprise a spe- in mouse and man has been found to map to chromo-
cific subset of cerebral dysrhythmias, rather than an somal positions of genes for the dominant modes of
inevitable result of any defect in membrane excitability neuronal inhibition.
or synaptic strength. Epilepsy is a disorder of recurrent,
When a gene for epilepsy is identified, what more do
spontaneous episodes of aberrant synchronization in
we need to know? The recent elegant descriptions of
neural networks that can remain local, spread to other
Na1, K1, and Cl2 channel defects in striated and cardiac
sites, or engage all cortical regions simultaneously. Neo-
muscle excitability syndromes seem to imply that in
cortical or hippocampal circuits are always activated
some systems only the position of the mutated codon
during an epileptic seizure; synaptically linked down-
and the resultant channel biophysics are required to
stream regions are recruited in ways that serve to am-
solve the disease phenotype. But there are other vari-plify or limit the discharge in time and space. Epilepsy is
ables. How else can we account for the individual differ-not myoclonus, a discharge usually arising in subcortical
ences in onset, penetrance, and progression of the samecircuits that gives rise to a sudden unitary or rhythmic
inherited mutation when examined on different geneticmuscle contraction involving the body, limbs, or a lim-
backgrounds, a phenomenon seen both in human andited muscle group. Nor is it the appearance of a seizure
in mouse mutants alike? Much of this phenotypic jitterfollowing a stimulus, since the capacity for afterdis-
must depend on compensatory gene activity; thereincharge is inherent in all higher nervous systems and is
lies the major source of uncertainty in localizing thereadily potentiated. The classification of inherited epi-
origin of epilepsy amidst the plasticity of the nervouslepsy syndromes has helped to differentiate between
system.seizure phenotypes that arise at different ages, show
Whether or not the fortuitous mutant models actuallycharacteristic electroencephalograph (EEG) or behav-
correspond to naturally occurring genes for human epi-ioral patterns, or exhibit specific anticonvulsant sensitiv-
lepsies, they define key sites of vulnerability in the ner-ity. The pathophysiology of the bursting circuit in differ-
vous system's formidable array of inhibitory controlent syndromes is of particular interest, since a large
mechanisms. The fascination now rests in analyzing thenumber of defects can enhance excitability in neural
categories of molecules they encode (Table 1) and innetworks, but fewer can also account for the prolonged
pursuing the essential question: how does the excitabil-periods of normal brain function characteristic of many
ity defect lead to intermittent cortical dysrhythmia?seizure disorders. Two principal challenges are to ex-
Those mutations that perturb multiple steps are perhapsplain the conditional behavior of the phenotype and to
the most important to evaluate, since it is these interven-find thecorrect molecular targets for the large fraction of
ing mechanisms, rather than the targets we already un-human lesions that are inexplicably resistant to current
derstand, that offer a cascade of new molecular entryanticonvulsants.
points to reverse the lesion in the developing brain priorSelecting the Candidates
Targeted mutations open the possibility of tracing the to the clinical onset of epilepsy.
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Table 1. Single Gene Deletion/Overexpression Mutants with Epileptic Phenotypes




5-HT2c Serotonin receptor ,5 Weeks 1 Tecott et al., 1995
Synapsin I, II Vesicle protein .2 Months 2 Rosahl et al., 1995
CaMKIIa Ca21/calmodulin protein kinase 2 Butler et al., 1995
TNAP Nonspecific alkaline phosphatase 2 Weeks 1 Waymire et al., 1995
Centromere BP-B (ins) Brain-specific DNA binding protein 3±4 Months 2 Toth et al., 1995
mKv1.1 K1 channel 2 Weeks 1 Smart et al., 1995
Weaver (spon) G protein±coupled inward rectifier (GIRK2) Adult 1 Patil et al., 1995
GluRB Q/R site editing of glutamate receptor 2 Weeks 1 Brusa et al., 1995
Subunit
Overexpression
GAP-43 Neural growth-associated protein .4 Weeks 2 Aignier et al., 1995
Plp Myelin proteolipid protein ,4 Weeks 1 Kagawa et al., 1994
No seizures, increased threshold for epileptogenesis
fyn Tyrosine kinase receptor Cain et al., 1995
TPA Tissue plasminogen activator Tsirka et al., 1995
BDNF (2/1) Brain-derived neurotrophin Kokaia et al., 1995
Targeting Intrinsic Excitability: ultrastructural evidence against the interesting possibil-
Ion Channel Genes ity that seizures might arise through preferential loss of
K1 channel blockers are potent convulsants; the deletion inhibitory transmitter release in the neocortex.
of mKv1.1, 1 of 16 murine homologs of the Shaker gene, Ca21/calmodulin-dependent protein kinase II (CaMKII)
eliminates a delayed rectifier K1 channel, resulting in phosphorylates an array of proteins critical to neuronal
a lethal epilepsy phenotype (Smart et al., 1995, Soc. signaling, including the synapsins, and is abundant in
Neurosci., abstract). The mKv1.1 subunit is expressed neocortex and hippocampus. Mice homozygous for a
widely in the neuraxis, with a subcellular localization null mutation of theCaMKII a subunit show spontaneous
that includes the presynaptic axon terminal. Thus, loss seizures generalizing from a limbic EEG discharge and
of this repolarizing current should potentiate transmitter lethal stimulus-induced amygdalar seizures (Butler et
release. Once the extent of other potential patterns of al., 1995). The hippocampal hyperexcitability is associ-
activity-dependent abnormal gene expression isdefined atedwith the reduction of two forms of long-term plastic-
and correlated with seizure onset, this mutant may pro- ity at these synapses. One point of convergence for
vide one of the most parsimonious experimental models the synapsin and CaMKII null mutants involves their
of cellular epileptogenesis. participation in the plasticity of evoked transmitter
The gene for the weaver (wv) mutant hasbeen found to release. Interestingly, synapsin deletion reduces hippo-
be a brain G protein±coupled inward rectifier K1 channel campal posttetanic potentiation with no effect on long-
(GIRK2) containing a missense mutation replacing a Gly term potentiation, while CaMKII deletion shows the
with a Ser at residue 156 (Patil et al., 1995). The substitu- opposite behavior. Whethereither of thesepatterns con-
tion lies in a conserved transmembrane domain of tributes to the underlying mechanism of epileptogenesis
GIRK2 where permutations occlude or alter channel has not been resolved.
conductance, but the effects on cellular membrane
Reduction in GABAergic neurotransmission produces
properties are still unknown. The expression of GIRK2
seizures; this mechanism was triggered from a distance
in neocortex is compatible with the appearance of sei-
by targeting pyridoxal phosphate (plp) metabolism withzures in wv heterozygotes but does not explain their
a deletion of the gene for tissue nonspecific alkalinelate onset. The severe cellular migration defect seen in
phosphatase (Waymire et al., 1995). Absence of the en-wv homozygotes may signal the contribution of second-
zyme (which converts plp to pl, the nonphosphorylatedary developmental network defects; however, even
form of vitamin B6 that crosses cell membranes, wherestriking architectonic rearrangements are not necessar-
it is subsequently reconstituted by pyridoxal kinase) re-ily epileptogenic; reeler mice, which have a severe mi-
sults in a 20-fold elevation of plp serum levels and largegration defect in cortical structures, show no evidence
reductions in intracellular brain plp levels. Plp is an es-of behavioral or electrographic seizures (Noebels, 1995).
sential cofactor for many enzymes, catalyzing reactionsTargeting the Synapse: Release
involving a amino acids, including glutamic acid decar-Mechanisms and Transmitters
boxylase, which synthesizes GABA. Significant brainVesicle proteins mediate the probability of transmitter
GABA reductions are present at 2 weeks postnatal inrelease and provide a novel site and mechanism for
the TNAP2/2 mutant, followed by lethal tonic±clonic con-inherited epilepsy.Deletion of the synapsin I and II genes
vulsions. Rescue of the seizure phenotype and correc-leads to nonlethal spontaneous seizures in mice; the
tion of GABA levels can be achieved with daily pyridoxaldouble mutant shows the most severe disorder (Rosahl
treatment. This mutant provides a highly instructive ge-et al., 1995). Vesicle numbers are evenly reduced in both
symmetric and asymmetric cortical synapses, providing netic model of vitamin B6±deficient seizures.
Minireview
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Targeting Synaptic Receptors: Excitatory specific steps in posttraumatic and postinfectious sei-
zure disorders. Targeting oligodendroglia by overex-and Neuromodulatory
Two new mutants provide unexpected examples of how pression of wild-type copies of the myelin proteolipid
protein gene causes a demyelinating syndrome leadingmutations in the ionic selectivity or permeability of a
postsynaptic receptor can lead to a progressive epi- to tremor and convulsions (Kagawa et al., 1994). In these
glial mutants, theclinical onset and neurologicalseveritylepsy syndrome. One mutation targets the enzyme that
mediates the posttranscriptional conversion of a geno- are tightly dependent on transgene copy number.
Human Epilepsy Mutationsmically encoded Gln codon to an Arg codon in the mRNA
of the GluRB receptor. The wild-type conversion results New human epilepsy syndromes continue to be mapped
(Ryan, 1995), including a recent report in Neuron (EksË i-in a charged Arg residue within the second hydrophobic
domain of the GluRB (AMPA-type) receptor subunit, the ogÆ lu et al., 1996) of a gene locus for periventricular neu-
ronal heterotopias with seizures, but the basis for aber-element responsible for the low divalent cation perme-
ability of the heteromeric AMPA-sensitive glutamate re- rant synchronization in these lesions remains elusive.
The first example of an autosomal gene defect involvingceptor. The intron immediately downstream is essential
for accurate editing. When this site is eliminated, the a membrane excitability protein, the nicotinic acetylcho-
line receptor a4 subunit, has been identified by posi-mutant mouse expresses reduced levels of edited
GluRB subunits; the resultant increase in Ca21 perme- tional candidatecloning of a single pedigree with a dom-
inant frontal lobe seizure syndrome beginning inability through AMPA channels produces altered pat-
terns of secondary immediate-early gene expression childhood (Steinlein et al., 1995). The missense mutation
replaces Ser with Phe at codon 248 in the second trans-(Brusa et al., 1995). Beginning in the third postnatal
week, heterozygous mutants show spontaneous recur- membrane domain, coincident with the position where
other site-directed substitutions have impaired porerent behavioral seizures suggestive of a limbic origin;
all mice die by postnatal day 20 and exhibit neuronal function. The subunit is expressed in frontal neocortex,
but there is little evidence linking the inhibition of nico-degeneration within this region.
Targeted deletion of the 5-HT2c gene, which encodes tinic receptors to paroxysmal bursting, and the wide-
spread distribution of the subunit in the remainder ofa G protein±coupled serotonin receptor, results in lethal
spontaneous seizures in male hemizygotes beginning the brain does not explain the limited zone of hyperexcit-
ability. Mice homozygous for a b2 subunit gene deletionin the fifth postnatal week (Tecott et al., 1995). In wild-
type mice, both agonists and antagonists of the 5-HT2c lack high affinity nicotine binding in the brain, and the
neurons are insensitive to applied nicotine. These mu-receptor alter induced seizure parameters in a manner
consistent with the null mutation; however, brief phar- tants have not been reported to show seizures, and
based on behavioral testing in an associative memorymacologic blockade of the receptor does not elicit spon-
taneous seizures, suggesting that the primary defect in task, appear, interestingly, to perform better without
them (Picciotto et al., 1995).serotonergic neuromodulation may still not be solely
responsible for the epileptic trait. These examples highlight the recurring concern of
whether, even in the case of a missing single channelTargeting the Network: Axon Terminal
Growth, Synaptogenesis, and Glia subunit, the excitability phenotype can be directly ex-
plained in terms of the mutant channel behavior withoutGene overexpression mutants complement deletion
strategies to alter the balance of excitability in neural looking for new and potentially deleterious patterns of
cellular plasticity. Like the molecular homeostatic re-circuits. Postnatal overexpression of the growth cone±
associated protein GAP-43 induces mossy fiber axon sponse of supersensitivity that follows synaptic deaffer-
entation, the targeted loss of an endogenous source ofterminal sprouting in hippocampus after 4 weeks of age,
followed by the onset of spontaneous seizures (Aignier depolarization in the membrane may trigger the nucleus
to invoke new mechanisms of maintaining excitability.et al., 1995). While it is tempting to conclude that excess
recurrent excitation in the hippocampus alone might A more clear understanding of the intervening steps
between the loss of a4 nicotinic receptor subunits andprovoke seizures, other synapses are undoubtedly af-
fected; evidence for interneuron loss in the mutant sug- paroxysmal EEG patterns awaits the construction of a
homologous mutant mouse model.gests that hyperinnervation may lead to cell death and
disinhibition in some circuits. Interestingly, the corre- From Target to Therapy
In medieval art it was traditional to show a demon ema-sponding GAP-43 null mutant develops axon pathfind-
ing defects that should also result in excitatory synapse nating from a suffering epileptic at the conclusion of a
seizure, with concern clearly evident regarding its inevi-imbalance; however, these mutants do not exhibit a
spontaneous seizure phenotype (Strittmater et al., table reappearance. In this century, anticonvulsant
drugs have been developed for their ability to control,1995).
Cytokines are important mediators in pathophysio- rather than prevent or reverse, seizure disorders. Has
the strategy for a rational search for definitive therapylogic processes, and astrocytosis is a prominent feature
of human epileptic foci. Overexpression of interleukin- of certain epilepsies finally unfolded, and is that goal
within reach? What is clear is that few inherited epilep-6 (IL-6), under the control of the glial fibrillary acidic
protein promoter sequence, produces a degenerative sies will be correctly interpreted in transgenic mutants
without assessing specific compensatory pathways;seizure syndrome in mice (Campbell et al., 1993). Since
inflammatory cytopathologic responses include the dra- these intermediate steps may provide the most realistic
insight into modifying the disease process. Phenotypicmatic up-regulation of many cytokines, this strategy may
provide a set of experimental gene models that isolate rescue by replacement of a missing gene product after
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Tecott, L.H., Sun, M.S., Akana, S.F., Strack, A.M., Lowenstein, D.H.,the onset of seizures, where possible, provides an im-
Dallman, M.F., and Julius, D. (1995). Nature 374, 542±545.portant a posteriori test to discriminate primary from
Toth, M., Grimsby, J., Buzsaki, G., and Donovan, G.P. (1995). Naturesecondary mechanisms in mice, but in clinical syn-
Genet. 11, 71±75.dromes the damage may already be done.
Tsirka, S.E., Gualandris, A., and Amaral, D.G. (1995). Nature 377,Nevertheless, the extraordinary bounty of epilepsy
340±344.
models from geneticists' laboratories will continue to
Waymire, K.G., Mahuren, J.D., Jaje, J.M., Guilarte, T.R., Coburn,provide new and otherwise unobtainable parts of the
S.P., and MacGregor, G.R. (1995). Nature Genet. 11, 45±51.
puzzle. There are more such models to come, and they
will both confirm predictions and yield surprises, such
as the absence of an epileptic phenotype in mice lacking
the Kv3.1 K1 channel (Ho and Joho, 1995, Soc. Neu-
rosci., abstract), and the GABAR b3 subunit (Culiat et
al., 1995). Transgenic expression of human mutations
in mouse models will allow critical epileptogenic steps
to be traced and assigned to appropriate categories,
while the mutants themselvesserve as reproducible bio-
logical test systems for therapeutic discovery. Ulti-
mately, these epilepsy models will not only help relieve
the human condition but also provide insights into gene
control of more subtle fluctuations of excitability, syn-
chronization, and plasticity in neural networks.
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